Évolution du préservatif féminin

Un des principaux objectifs du programme commun d’UAFC et de FCMi est d’accroître la variété des préservatifs mis à disposition des usagers. Dans l’actualité, une grande variété de préservatifs féminins est en cours de conception et de fabrication par différents producteurs et ils en sont à différents stades de disponibilité sur le marché. Nous avons divisé ce processus en trois grandes étapes. Pour plus de détails sur chaque préservatif féminin, cliquez sur le nom du produit.

Product Development product undergoing clinical testing or awaiting regulatory approval, etc but has not yet reached the market

Local Market Access product available in certain countries but not yet eligible for bulk procurement by UN or USAID agencies

Eligible for Bulk Procurement product is eligible for bulk procurement by UN or USAID agencies, i.e. WHO/UNFPA prequalified or USFDA approved

Cupid®  

100%

WHO/UNFPA prequalified since July 2012. Initiated the USFDA approval process in 2012. The product holds the CE marking and is distributed in India, Brazil, Indonesia, The Netherlands, South Africa, Mozambique and Kyryz Republic.

FC2®  

100%

Available in 143 countries and holds CE marking. WHO/UNFPA prequalified since 2007 and USFDA approved in 2009. Available in 143 countries and holds CE marking. WHO/UNFPA prequalified since 2007 and USFDA approved in 2009.

Velvet  

100%

Currently being assessed by Functionality Study II, the results of the study will be part of the product dossier to be submitted for WHO/UNFPA prequalification.

Woman's Condom  

100%

Holds South Africa Bureau of Standards (SABS) certification mark and CE mark. Is approved by the Shanghai Food and Drug Administration. Currently under review for WHO/UNFPA prequalification.

Phoenurse®  

66%

Holds CE marking.

VA w.o.w.®  

66%

Holds CE marking and is available in the private sector in several countries including South Africa, Brazil and India. Product dossier has been submitted to WHO/UNFPA for prequalification.

Cupid2®  

66%

Currently being assessed by Functionality Study II the results of the study will be part of the product dossier to be submitted for WHO/UNFPA prequalification.

OrigamI™ FC  

33%

Currently not available commercially. Expected to reach the market in late 2015, pending regulatory pre-market approvals.